Vascular endothelial growth factor: A potential target of therapy in neuromyelitis optica?

E-ISSN： 1759-1961|6|4|349-350

ISSN： 1759-1961

Source： CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol.6, Iss.4, 2015-11, pp. : 349-350

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractAn open study was conducted to evaluate the safety of bevacizumab, anti‐vascular endothelial growth factor antibody, in patients with neuromyelitis optica developing signs of relapse.

Related content

The role of granulocyte‐macrophage colony‐stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. S1, 2015-12 ,pp. : 70-77 (8)

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab is safe in acute relapses of neuromyelitis optica

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. 4, 2015-11 ,pp. : 413-418 (6)

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of multiple sclerosis and neuromyelitis optica in pregnancy and childbearing

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. 1, 2015-02 ,pp. : 93-98 (6)

John Wiley & Sons Inc

Access to resources Recommend Favorite

Case of neuromyelitis optica spectrum disorder with atopic factors

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. 2, 2015-05 ,pp. : 170-171 (2)

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of Vascular Endothelial Growth Factor Based on Gold Nanoparticles and Immunoreaction Using Resonance Light Scattering

By Chen Zhanguang

Plasmonics, Vol. 8, Iss. 2, 2013-06 ,pp. : 605-611 (7)

Springer Publishing Company

Access to resources Recommend Favorite